Access cutting-edge interstitial lung diseases treatment through this phase 3 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Los Angeles location
Preparing your pre-screening questions…
Access interstitial lung diseases specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related interstitial lung diseases treatment provided free
Check if you qualify for this interstitial lung diseases clinical trial in Los Angeles, CA
No-Cost Study Care
Local to Los Angeles
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression. Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Sponsor: Boehringer Ingelheim
Yes, this clinical trial (NCT07540988) has an active research site in Los Angeles, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for interstitial lung diseases treatment options in Los Angeles, CA, this clinical trial (NCT07540988) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced interstitial lung diseases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all interstitial lung diseases clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Los Angeles — not just this study.
Browse Ankylosing Spondylitis Trials in Los Angeles →